Avanos Medical, Inc. (NYSE:AVNS) has received an average recommendation of “Hold” from the seven brokerages that are currently covering the stock, MarketBeat Ratings reports. Two analysts have rated the stock with a sell recommendation, two have given a hold recommendation and two have given a buy recommendation to the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $40.33.
Several equities research analysts recently weighed in on the company. Zacks Investment Research lowered Avanos Medical from a “hold” rating to a “sell” rating and set a $50.00 price target on the stock. in a research report on Wednesday, January 27th. KeyCorp lifted their price target on shares of Avanos Medical from $47.00 to $55.00 and gave the company an “overweight” rating in a research report on Friday, January 8th. Finally, Morgan Stanley raised their target price on shares of Avanos Medical from $36.00 to $45.00 and gave the company an “underweight” rating in a research note on Tuesday, December 15th.
Shares of Avanos Medical stock opened at $45.28 on Thursday. The company has a current ratio of 3.16, a quick ratio of 2.14 and a debt-to-equity ratio of 0.19. Avanos Medical has a 12-month low of $19.46 and a 12-month high of $53.61. The company has a market cap of $2.17 billion, a P/E ratio of 156.14, a PEG ratio of 6.50 and a beta of 1.12. The company’s fifty day simple moving average is $47.74 and its two-hundred day simple moving average is $40.62.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. BlackRock Inc. lifted its stake in Avanos Medical by 3.4% during the 4th quarter. BlackRock Inc. now owns 5,323,341 shares of the company’s stock valued at $244,235,000 after acquiring an additional 177,432 shares during the period. Champlain Investment Partners LLC boosted its holdings in Avanos Medical by 0.8% in the third quarter. Champlain Investment Partners LLC now owns 3,380,740 shares of the company’s stock worth $112,308,000 after purchasing an additional 27,085 shares during the last quarter. Victory Capital Management Inc. grew its position in Avanos Medical by 1.9% in the 4th quarter. Victory Capital Management Inc. now owns 2,095,788 shares of the company’s stock worth $96,155,000 after purchasing an additional 38,731 shares during the period. Bank of New York Mellon Corp raised its stake in Avanos Medical by 6.6% during the 4th quarter. Bank of New York Mellon Corp now owns 623,686 shares of the company’s stock valued at $28,615,000 after buying an additional 38,676 shares during the last quarter. Finally, Nuveen Asset Management LLC lifted its holdings in shares of Avanos Medical by 4.8% during the 4th quarter. Nuveen Asset Management LLC now owns 237,997 shares of the company’s stock valued at $10,919,000 after buying an additional 10,866 shares during the period. Institutional investors own 94.80% of the company’s stock.
About Avanos Medical
Avanos Medical, Inc operates as a medical technology company that focuses on delivering medical device solutions to improve patients' quality of life in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. Its product portfolio includes digestive health products, including enteral feeding tubes and solutions; respiratory health products, such as closed airway suction systems and oral care kits; and acute pain products comprising surgical pain pumps, and cold and compression therapy systems, as well as interventional pain management solutions that include minimally invasive interventional pain therapies.
Receive News & Ratings for Avanos Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avanos Medical and related companies with MarketBeat.com's FREE daily email newsletter.